MAGNESIUM-SULFATE PROPHYLAXIS AFTER CARDIAC OPERATIONS

One hundred patients undergoing elective cardiac operations were rando mized into placebo (n = 54) and magnesium (n = 46) groups. The magnesi um group received six doses of 2.4 g (19.2 mEq) magnesium sulfate intr avenously in the first 24 hours after the cardiac operation. The magne sium group had higher serum magnesium concentrations postoperatively ( 1.09 +/- 0.20 versus 0.75 +/- 0.13 mmo/L; p < 0.0001), postoperative d ay 1 (1.49 +/- 0.34 versus 0.70 +/- 0.12 mmol/L; p < 0.0001) and posto perative day 2 (0.96 +/- 0.19 versus 0.76 +/- 0.07 mmol/L; p < 0.0001) . Patients in the magnesium group had a lower incidence of ventricular tachyarrythmias (VTs) (17.3% versus 51.9%; p = 0.0006), less need for treatment (6.5% versus 20.3%; p < 0.0001), fewer VT episodes/patient (0.3 +/- 0.8 versus 1.39 +/- 1.9; p < 0.0001), and a reduction in the severity of VTs as measured by the modified Lown grade (p = 0.0002). N o differences were demonstrated with respect to supraventricular tachy arrythmias. The magnesium group had reduced absolute creatine kinase-M B levels (5.3 +/- 4.2 versus 28.4 +/- 28 IU/L; p = 0.001) as well as c reatine kinase-MB fraction (0.01 +/- 0.02 versus 0.05 +/- 0.04; p = 0. 001) on postoperative day 1. Serum magnesium concentrations were lower during VTs than during periods of sinus rhythm (0.75 +/- 0.75 versus 1.02 +/- 0.35 mmol/L; p < 0.001). Patients with VTs had higher serum c reatine kinase-MB levels than those that did not both postoperatively (32.7 +/- 26 versus 23.0 +/- 14.7 IU/L; p 0.04) and on postoperative d ay 1 (29.7 +/- 32 versus 10.3 +/- 11.7 IU/L; p = 0.019). Magnesium sul fate prophylaxis prevents hypomagnesemia and reduces the incidence and severity of VTs postoperatively, possibly by enhancing myocardial pro tection.